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ABSTRAK 
 
PENGESANAN ANTIBODI TERHADAP SEL DARAH MERAH DI KALANGAN 
PESAKIT YANG MENGALAMI KEGAGALAN BUAH PINGGANG YANG 
KRONIK DAN PERNAH MENERIMA TRANSFUSI DARAH, DI HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
 
Pengenalan : Penghasilan antibodi terhadap sel darah merah adalah salah satu komplikasi 
yang penting dan kerap berlaku kepada pesakit yang kerap menerima transfusi darah. 
Pesakit yang menghidap masalah kegagalan buah pinggang sangat mudah untuk 
mengalami kekurangan darah merah. Ini mennyebabkan pesakit-pesakit yang mempunyai 
kegagalan buah pinggang memerlukan pemindahan darah yang lebih kerap. Tujuan utama 
kajian ini dijalankan adalah untuk melihat kelaziman dan jenis antibodi terhadap sel darah 
merah dan juga faktor risiko yang terdapat dikalangan pesakit yang mengalami kegagalan 
buah pinggang dan pernah menerima transfusi darah. 
 
Metodologi: Kajian keratan lintang ini telah dijalankan di Unit Perubatan Transfusi 
Darah Hospital Universiti Sains Malaysia selama satu tahun daripada Januari 2016 
sehingga Januari 2017. Seramai 249 pesakit yang mengalami masalah kegagalan buah 
pinggang telah diambil sebagai subjek ujikaji. Semua pesakit ini telah menerima transfusi 
darah sekurang-kurangnya satu unit darah merah. Sampel darah pesakit telah diproses 
dan sera pula digunakan untuk ujian saringan antibodi. Sampel darah yang positif 
saringan antibodi akan diproses selanjutnya untuk penentuan jenis antibodi yang lebih 
spesifik.   
 
xii 
 
Keputusan: Hasil daripada kajian ini, kami dapati kebanyakan subjek adalah lelaki 
(55.8%) dan golongan tua (55.8%) yang berumur lebih dari 60 tahun. Kebanyakan pesakit 
yang memerlukan pemindahan darah adalah pesakit yang mengalami kegagalan buah 
pinggang tahap akhir (tahap 4 dan tahap 5) iaitu 90.3%. Kekerapan pesakit yang 
mempunyai antibodi terhadap darah merah adalah 12.4%. Kebannyakannya adalah 
alloantibodi (96.8%) berbanding autoantibodi. Jenis antibodi yang paling kerap adalah 
antibodi anti Mia (40%) diikuti dengan anti E (22.8%). Penghasilan antibodi terhadap sel 
darah merah dipengaruhi sekiranya pesakit pernah mengandung sebelum pemindahan 
darah (p-value < 0.05). Faktor-faktor lain seperti sosiodemografi, tahap kegagalan buah 
pinggang, kekerapan hemodialisis, masalah penyakit yang lain dan jumlah bilangan darah 
yang diterima tidak mempengaruhi kepenghasilan antibodi terhadap sel darah merah. 
 
Kesimpulan: Kesimpulan daripada kajian ini menunjukkan pesakit yang mengalami 
masalah kegagalan buah pinggang juga mempunyai risiko yang tinggi untuk 
menghasilkan antibodi terhadap cell darah merah yang diterima daripada pesakit lain. 
Risiko adalah lebih tinggi sekiranya pesakit pernah mengandung. Hasil daripada kajian 
ini kami menyarankan pesakit yang meghidapi kegagalan buah pinggang memerlukan 
darah yang sesuai untuk semua rhesus antigen. 
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ABSTRACT 
 
DETECTION OF RED BLOOD CELL IMMUNIZATION AMONG 
TRANSFUSED CHRONIC KIDNEY DISEASE PATIENTS IN HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
 
Introduction: Red blood cell (RBC) immunization is a common complication in blood 
transfusion recipients. Patients with chronic kidney disease (CKD) eventually develop 
anaemia due to multifactorial and require regular blood transfusion which exposed patient 
for development of RBC antibody. The objectives of this study were to determine the 
incidence and specificity of RBC immunization and its risk factors among transfused 
CKD patients. 
 
Study design and methodology: This is a cross-sectional study which was done over 1 
year period from Jan 2016 until Jan 2017 in the Transfusion Medicine Unit Hospital 
Universiti Sains Malaysia. A total of 249 samples were collected from CKD patients who 
received at least one-pint blood transfusion which only match for ABO and RH(D) 
antigen. The blood samples (serum) were screened for the presence of antibody using 
antibody screening test. Samples with positive antibody screening will subjected for 
antibody identification. 
 
Result: The result showed majority of our study population were male (55.8%) and 
elderly with age > 60 years (55.8%). Majority of patients also at late stage of CKD (stage 
4 and 5) (90.3%) who require more blood transfusions. The prevalence of positive 
antibody screening among CKD patients were 12.4%. Among the patients who have 
xiv 
 
positive antibody screening, majority were alloantibody (96.8%). Anti Mia was the most 
common alloantibody (40%) followed by anti-E (22.8%). There was no significant 
association between sociodemographic background, stage of CKD, requirement of 
haemodialysis, underlying medical illness and number of packed cell transfusion with the 
development of RBC antibody. The only significant associated factor that we can prove 
was history of pregnancy (p-value < 0.05).  
 
Conclusion: As a conclusion, prevalence of RBC immunization was common among 
CKD patients and the risk were increased in patients who had history of pregnancy, 
therefore we proposed for rhesus RBC phenotyping in CKD patients especially patients 
in reproductive age and to supply blood match rhesus antigen blood.  
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
______________________________  
INTRODUCTION 
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1.0 GENERAL INTRODUCTION  
 
Chronic kidney disease (CKD) is one of the widespread health problem in the world and 
the prevalence is increasing worldwide. It is defined by an irreversible loss of renal 
function or decreased glomerular filtration rate for 3 or more months (Levey et al., 2003). 
The estimated prevalence of CKD in the US was 16.8%, while in Asian population the 
prevalence ranged from12.1% to 17.5%. In Malaysia, the incidence and prevalence of 
patient with end stage renal disease (ESRD) on dialysis had increased significantly from 
88 and 325 per million population (pmp) respectively in 2001 to 170 and 762 pmp 
respectively in 2009 (Ministry Of Health  2011). 
 
The increased in ESRD was largely driven by the increasing incidence of diabetic kidney 
disease (DKD) globally over recent decades. The prevalence of people with diabetic is 
expected to reach 642 million people by 2040 and accounting about 40% will develop 
CKD (Perkovic et al., 2016). It is reported that, Malaysia had the highest incident rate of 
patients with diabetes who entering renal replacement therapy (Huri et al., 2015). The 
growing number of ESRD places an enormous human, economic and social burden on 
the health care system. It is also associated with significant morbidity and mortality. 
 
One of the major medical issues facing by CKD population is anaemia. The causes of 
anaemia in patient with CKD are multifactorial. The most well-known cause is inadequate 
erythropoietin (EPO) production, which is often compounded by other factors including 
iron and folate deficiency, decreased red cell survival and accumulation of toxic inhibitors 
of erythropoiesis (Eschbach and Adamson, 1985; Hsu et al., 2002). Low haemoglobin 
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levels around 5-7g/dl were common especially in haemodialysis patients thus require 
frequent blood transfusions to improve the symptoms of anaemia (Kliger et al., 2012). 
Exposure to multiple blood transfusions inevitably lead to many undesirable outcomes, 
and one of the important and common outcome is development of RBC alloimmunization 
(Singer et al., 2000). 
 
Alloimmunisation is defined as development of antibodies in response to alloantigen after 
exposure to genetically different cells or tissue (Harmening, 2012). There are many 
factors which can influence the development of alloantibody in the blood. Many studies 
had showed that alloimmunisation formation are influence by the recipient’s immune 
status, dose of blood transfused and immunogenicity of the antigen. Therefore, ensuring 
that the antigens of transfused blood cells are match with recipient blood cells are 
essential for safe blood transfusion. Previous study showed that the rate of RBC 
alloimmunizations among patients with chronic blood transfusion such as 
hemoglobinopathy, aplastic anaemia, myelogenous leukaemia, upper gastrointestinal 
bleeding and chronic kidney disease was 29%, 11%, 16%, 11% and 14% respectively 
(Blumberg et al., 1983). So, these kinds of populations are at greater risk for developing 
red cell alloantibodies. 
 
In view of the great concern regarding alloimmunisation among chronically transfused 
patients, many extensive studies were conducted involving thalassemia patients and 
sickle cell disease but only a few numbers of study assessing risk of RBC immunization 
among CKD patients. So, we chose CKD population for this study because this disease 
display pattern of increasing in trend thus patients are at risk for multiple blood 
transfusions. The dialysis acceptance and also prevalence rate in Malaysia have almost 
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double in recent years. For instance, dialysis acceptance was 1733 per million population 
(pmp) in 2004 and increasing to 3156 pmp in 2013. In National Renal Registry 2014, the 
total number of patients on dialysis has increased sharply from 6702 in 2000 to 31 637 in 
2013, causing a significant strain on Malaysian health resources (Begum et al., 2016). 
 
Local data regarding the rate of RBC alloimmunisation has been reported in a study done 
in Universiti Kebangsaan Malaysia medical centre (PPUKM) which ranging from 5-30% 
among the multiply transfused patients (Yousuf et al., 2013). Red cell alloimmunisation 
may lead to difficulty in finding the compatible blood for transfusion and might cause 
haemolytic transfusion reaction if the antibodies are not detected during pre-transfusion 
testing.  
 
The presence of alloantibodies will create significant problems in transfusion therapy and 
can contributes to morbidity and mortality. This will result in difficulty for cross-
matching of the blood especially during emergency. A clinically significant 
alloantibodies are capable of causing mild to severe red cell haemolysis (Poole and 
Daniels, 2007). Furthermore, autoantibody which present can mask the existence of 
alloantibody and this will complicate the situation. Autoantibody is an antibody that 
produced against the patient’s own red cells. This autoantibody may prematurely destroy 
the RBC in certain circumstances and lead to immune haemolysis (autoimmune 
haemolytic anaemia, AIHA) (Petz and Garratty, 2004). These conditions are relatively 
unusual but may contribute to significant clinical problems which require attention of 
knowledge among the clinicians and laboratory personnel’s. The most common form of 
AIHA is characterized by the presence of ‘warm’-type autoantibodies which are 
immunoglobulin G (IgG) (Hoffbrand et al., 2016). IgG type of immunoglobulin capable 
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to react optimally at 37 0C and causing extravascular RBC destruction by tissue 
macrophages (Petz and Garratty, 2004). The presence of autoantibody will mask the 
presence of alloantibody during antibody identification and may cause difficulty to 
provide compatible blood for these patients. 
 
In view of very few data have been reported concerning alloantibody/autoantibody 
development in CKD patients, especially local data in Malaysia, this study is conducted 
to look for the incidence and risk factors in CKD patients for development of RBC 
immunization. Hopefully the result can be used for better comprehension of the problems 
and provide the ideal approach for transfusion policy in CKD population. 
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LITERATURE REVIEW 
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2.1 CHRONIC KIDNEY DISEASE 
 
2.1.1 Definition, Prevalence and Classification 
  
Chronic kidney disease is a term referred for heterogenous disorders affecting the 
structure and function of the kidney (Levey and Coresh, 2012). It is defined by the 
presence of kidney damage signs (including albuminuria, haematuria or proteinuria), 
decreased kidney function evidence by reducing GFR and abnormal imaging and 
histology lasting for three months or more (Ayodele and Alebiosu, 2010). Table 2.1 
describe the criteria for definition of chronic kidney disease. 
 
During the 20th century, infectious disease are the major health problems, however in this 
recent years, non-infectious disease has replaced the infectious disease and become the 
major cause of morbidity and mortality worldwide (Atkins, 2005; Nahas, 2005). It has 
been estimated about 80% of the disease burden occur in low and middle income 
countries and about 25% involve people less than 60 years old (Le Galès-Camus et al., 
2005). Chronic kidney disease has emerged as a global public health problem as the 
prevalence is increasing in trend. Based on World Health Report 2002 and Global Burden 
of Disease (GBD) project, the kidney disease and urinary tract cause deaths for 
approximately 850,000 every year (Schieppati and Remuzzi, 2005). It has high potential 
to progression to end-stage renal disease and cause a devastating medical, social and 
economic burden for the patient, family and country. In developed countries, ESRD is a 
major cost for health-care system and annual requirement of renal replacement therapy 
continue to increase between 6%-12%. This problem more prominent in developing 
countries. Over 2 million people now require haemodialysis to sustained life worldwide 
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and this estimation still lower than real numbers (Eggers, 2011). Effort to reduce the cost 
for management of the disease is difficult to achieved and many countries cannot afford 
renal replacement therapy. In 112 developing countries with combined population of over 
600 million peoples, about 1 million patients died due to untreated kidney failure 
(Barsoum, 2006).  
 
According to the 2010 US Renal Data System Annual Data Report, the primary causes of 
kidney disease are diabetes with incidence of ESRD 153 pmp in 2009, hypertension (99 
pmp), glomerulonephritis (23.7 pmp) (Bakris and Collins, 2008) and cardiovascular 
disease. However about 28% of CKD patients who are elderly with age more than 60 
have neither diabetic nor hypertensive (Vassalotti et al., 2010). Same findings were also 
observed in developing countries but surprisingly glomerulonephritis and CKD of 
unknown origin have account for larger fraction of the total incidence, especially in young 
population (Sharma et al., 2010). 
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Table 2.1: Criteria for definition of Chronic Kidney Disease 
 
Adapted from Chronic Kidney Disease, Levey 2012 
10 
 
Chronic kidney disease is classified into five stages. This classification is divided 
according to the glomerular filtration rate and albuminuria. GFR is the best measurement 
of overall kidney function. It is estimated from serum creatinine measurements by using 
the Modification of Diet in Renal Disease study equation based on age, sex, race and 
calibration for serum creatinine. Normal range for young adult is approximately 120 to 
130mL/min per 1.73m2. Level of less than 60 mL/min per 1.73m2 will represent loss of 
half of the normal renal function. GFR level more than 90 mL/min per 1·73 m² (stage 1), 
60–89 mL/min per 1·73 m² (stage 2), 30–59 mL/min per 1·73 m² (stage 3), 15–29 mL/min 
per 1·73 m² (stage 4), and less than 15 mL/min per 1·73 m² (stage 5) (Levey and Coresh, 
2012). Table 2.2 showed stages of CKD patients (stage 1 to 5) based on GFR level. 
 
The worldwide prevalence of CKD and end stage renal failure are increasing in trend. 
The prevalence are somehow varies in each countries such as in U.S (13.1%), Taiwan 
(9.8-11.9%), Norway (10.2%), Japan (12.9-15.1%), China (3.2-11.3%), Korea (7.2- 
13.7%), Thailand (8.45-16.3%), Singapore (3.2-18.6%), and Australia (11.2%) 
(HWANG et al., 2010). The discrepancies of the prevalence were attributed by multiple 
factors such as age, ethnic groups, survey policies and equations of estimated glomerular 
filtration rate calculation. For instance, National Kidney Foundation, US has standardized 
the diagnosis and staging of CKD based on eGFR. 
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Table 2.2: Classification of CKD based on GFR level, Prevalence and Action Plan for each 
Stages of Chronic Kidney Disease. 
 
 
* GFR glomerular filtration rate.  
‡ Prevalence for stage 5 is from the U.S. Renal Data System (1998); it includes approximately 
230 000 patients treated with dialysis and assumes 70 000 additional patients not receiving 
dialysis. Prevalence for stages 1 to 4 is from the Third National Health and Nutrition Examination 
Survey (1988 to 1994). Population of 177 million adults age 20 or more years.  
§ Includes actions from preceding stages  
Table adapted from National Kidney Foundation Kidney Disease Outcome Quality Initiative Classification, 
Prevalence, and Action Plan for Stages of Chronic Kidney Disease, 2003  
 
 
In Malaysia, the incidence and prevalence of end stage renal disease patients on dialysis 
have dramatically increased with estimated prevalence around 9%. The prevalence of 
ESRD on dialysis has risen markedly from 352 pmp in 2001 to 975 pmp in 2012 (Salman 
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et al., 2015). The main contributing factors to the disease are hypertension, primary 
kidney disease, diabetes and ischaemic heart disease. Other risk factors that also involve 
such as ethnic group, age, obesity, high cholesterol, family history and smoking. 
 
2.1.2 Anaemia in Chronic Kidney Disease  
 
a) Definition of anaemia and background  
 
European Best Practice Guidelines (EBPG) has defined anaemia in CKD patients are 
based on their gender and age. The haemoglobin value of <11.5 g/dl in women and <13.5 
g/dl in men (<12 g/dl in those aged >70 years) is considered below normal limit. Anaemia 
work-up should be commenced when haemoglobin levels fall below these limits (Collins 
et al., 2003). In the 2013 update, Kidney Disease Outcome Quality Initiative (KDOQI) 
has modified this definition, and the new criteria for diagnosing of anaemia in adult males 
are haemoglobin <13.5 g/dl (Haemoglobin ≤ 13.2g/dl in men > 70 years of age) and <12 
g/dl in adult females all ages (Locatelli et al., 2013). 
 
In chronic kidney disease, anaemia is the most important haematological abnormality and 
its management has been improvised by recombinant human erythropoietin (EPO). 
However, the used of EPO may lead to variable adverse clinical outcomes and also 
debilitating symptoms such as tiredness, lethargy, muscle fatigue, intolerance to cold, 
breathlessness on exertion and poor exercise activity. It also associated with high 
prevalence of cardiovascular disease and cause high morbidity. Mortality as a result of 
cardiovascular disease was reported approximately 50% in patients with chronic renal 
disease (London, 2003). Based on study done by McClellan et al, the prevalence of 
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anaemia is strongly associated with declining of GFR. Percentage of patients with 
haemoglobin ≤ 12 g/dL increased from 26.7% to 75.5% when GFR decreased from ≥ 60 
mL/min/1.73 m2 to < 15 mL/min/1.73 m2 (McClellan et al., 2004). In other report 
described the prevalence of anaemia was significantly increased as the creatinine 
clearance falls to < 70mls/min in males and < 50mls/min in females (Hsu et al., 2002). 
  
b) Pathophysiology of anaemia in chronic kidney disease  
 
Chronic anaemia is almost invariably consequences of chronic renal disease. The causes 
for development of anaemia in renal disease are multifactorial. As renal function 
deteriorates, there is progressive reducing in haemoglobin level and the features will be 
more evidence once the GFR level reduce to less than 30 ml/min (Astor et al., 2002). The 
type of anaemia is commonly normochromic normocytic anaemia which will associate 
with the presence of echinocytes (burr cells) in the blood film (Figure 2.1). The 
reticulocyte count is usually normal or slightly low, and the bone marrow will show 
normoblastic erythropoiesis without the erythroid hyperplasia which are expected at that 
level of anaemia. Patients who have undergone nephrectomy are prone to be more 
severely anaemic compared to patients with polycystic disease (Hoffbrand et al., 2016). 
Blood volume studies will show a reduced RBC mass, but normal total blood volume. 
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Figure 2.1: Peripheral blood film in chronic kidney disease, showing acanthocyte and ‘burr’ cells. 
Figure adapted from journal Anaemia of chronic kidney disease, Macdougall 2007. 
 
The reduction of erythropoietin levels which occur in renal disease is the dominant cause 
of anaemia. This is result from loss of peritubular cells in the kidney which responsible 
for synthesis and secretion of EPO (Caro et al., 1979). The EPO level will be 
inappropriately low for the degree of anaemia in renal anaemia (Figure 2.2). EPO is the 
hormone which responsible for maintaining the proliferation and differentiation of 
erythroid precursor cells in the bone marrow. An increase of serum creatinine above 133 
μmol/L is significantly cause reduction of the plasma EPO and haemoglobin 
concentration, however there is no direct correlation between reduction of GFR and 
impairment of renal EPO production. Presence of circulating inhibitors of erythropoiesis 
also have been demonstrated, but they are not clinically significant. Red cell survival also 
shown to be diminished in renal disease patient, but this is also a minor factor (Hoffbrand 
et al., 2016). 
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Figure 2.2: The graph shows the relationship between haemoglobin and serum erythropoietin 
levels in non-renal anaemia and in patients with chronic kidney disease. The rectangle indicates 
the interquartile range and 95% confidence range of erythropoietin levels in non-anaemic healthy 
adults.  
Adapted from journal Anaemia of chronic kidney disease, Macdougall 2007. 
 
Many other factors can also contribute to aggravation of anaemia in chronic kidney 
disease. Iron deficiency is one of the common factors due to poor oral intake and 
increased iron losses. The latter may be caused by increased in blood loss through 
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gastrointestinal tract and exacerbate by frequent haemodialysis procedures. In addition, 
chronic immune activation arise from contact activation of immune cells by dialysis 
membrane and also infection (Weiss and Goodnough, 2005). Hyperparathyroidism which 
is a complication of renal disease may worsen the anaemia by inhibiting the erythropoiesis 
and fibrosis of the bone marrow. Uraemia state will reduce the RBC life span by causing 
low grade haemolysis. Folate deficiency also occur which mainly due to poor intake or 
excessive lose during haemodialysis (Table 2.3) (Macdougall, 2007). 
 
Table 2.3: Factors which contributing to renal anaemia. 
Factors for anaemia in chronic kidney disease 
Relative deficiency of erythropoietin 
Reduced RBC survival as a result of haemolysis 
‘Uraemic inhibitors’ of erythropoiesis 
Hyperparathyroidism with marrow fibrosis 
Aluminium toxicity 
Iron/folate deficiency 
Blood loss 
Adapted from Anaemia of chronic disease, Macdougall 2007. 
 
2.1.3 Management of anaemia and role of blood transfusion in CKD patients 
 
Management of renal anaemia is very crucial as this problem is very common among 
CKD patients. Multiple clinical practice guideline for the management of anaemia in this 
patients have been established such as in UK, NICE Guideline (Conditions, 2006), 
European Best Practice Guidelines in the Europe (Vaage-Nilsen, 2005) and in the US, 
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K/DOQI Guidelines (National, 2006). All these guidelines have offer similar 
recommendation regarding EPO therapy, monitoring of iron status and iron supplement. 
The European Renal Best Practice has organized the Kidney Disease: Improving Global 
Outcome (KDIGO) group which has produced a comprehensive guideline for the 
management of anaemia in CKD patients. Based on this guideline, it addressed all the 
important points including therapy with erythropoiesis stimulating agent (ESA), iron 
therapy, ESA resistance and also blood transfusion. It has been proved that correction of 
anaemia in CKD patients will improve the cardiac function (Hayashi et al., 2000), 
cognitive function (Pickett et al., 1999), quality of life and physical activity (Lim et al., 
1989). Based on the EBPG, the suggested haemoglobin target in CKD patients are ≥ 
11g/dl. The level of ≥14g/dl is undesirable in general, and the target for patients with 
concomitant cardiovascular disease is 12g/dl (Collins et al., 2003). Other randomized 
clinical trials have suggested that haemoglobin level of > 13 g/dl may increase risk of 
cardiovascular events (Besarab et al., 1998). 
 
 
a) Non-transfusion therapy  
 
Iron therapy is an important step in the treatment of anaemia in CKD. This is due to 
absolute or functional iron deficiency are common. Based on TREAT study, CKD 
patients also have element of iron deficiency despite of chronic disease itself. This finding 
has been proved as all patients in the control group able to maintain a relatively high mean 
haemoglobin level during follow up when receiving minimal darbepoetin alfa and iron 
therapy. This is concluded as many of these patients are not fully iron repletion (median 
transferrin saturation (TSAT) 23%, IQR 18-29%) (Pfeffer et al., 2009). Based on this 
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result, role of iron therapy is re-evaluated and not only be used for patients who are iron 
deficient but also in those who are apparently adequate iron stores. 
 
Guideline also recommend the possibility to perform a trial of iron therapy (intravenous 
or oral) when tolerated in anaemia CKD patients if an increase in haemoglobin level is 
desired. This treatment will be helpful in reducing the need for blood transfusion. Oral 
iron therapy should be used as first-line therapy for a minimum of 3 months in the absence 
of gastrointestinal intolerance for patients with mild to moderate anaemia. Intravenous 
iron is the first choice in severe anaemia or when oral iron is ineffective. This is especially 
in the condition with presence of absolute iron deficiency (TSAT <20% and serum ferritin 
<100ng/ml) or increase in haemoglobin level without starting erythropoietin is desired 
and TSAT is <25%, serum ferritin < 300ng/ml in dialysis patient (Locatelli et al., 2013). 
 
Erythropoietin therapy is effective in correcting the anaemia in patients with chronic 
kidney disease about 90-95%. Current recommendations suggesting erythropoietin 
therapy should be started if haemoglobin level falls below 10-11 g/dl (Macdougall, 2007). 
However, the initiation of ESA treatment needs to justify the potential benefit of reducing 
blood transfusion and anaemia related symptoms against the unfavourable risk in 
individual patient (such as stroke, vascular access loss and hypertension). A great caution 
must be done in case of CKD patients with active malignancy, had history of stroke or 
previous history of malignancy. Study has shown that targeting higher haemoglobin level 
in CKD population have association with higher risk for thrombosis, stroke and death 
(Palmer et al., 2010). In case of non-dialysis CKD patients with haemoglobin level ≥ 10 
g/dl, ESA initiation is not recommended (Pfeffer et al., 2009).  
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b) Red cells transfusion therapy  
 
Red cell transfusions are required to promote the oxygen-carrying capacity of the blood 
by increasing the haemoglobin level of patient with acute or chronic anaemia. However, 
blood transfusion for managing chronic anaemia is not recommended when possible, to 
minimize the related risk for their used (Murphy et al., 2001). This is especially, in case 
of patients who are eligible for kidney transplantation. This is related to the many 
unwanted complications of red cell transfusion particularly alloimmunization. Based on 
the guideline, blood transfusion in CKD patients are indicated for management of chronic 
anaemia if the benefit of red cell transfusion may outweigh the risk, such as in the 
condition that ESA therapy is ineffective, or risk of ESA therapy outweigh it benefit 
(Streja et al., 2008). 
 
Decision for blood transfusion in CKD patients should not be based on the haemoglobin 
level alone but must be based on occurrence of symptoms which caused by the anaemia 
(Locatelli et al., 2013). AABB guideline is also agreeable with this concept (Carson et 
al., 2011). Study done in FOCUS trial which has include the symptoms into the decision 
for blood transfusion. This trial has comparing patients in the restrictive group received 
transfusion if haemoglobin level was less than 8 g/dl or if patient were symptomatic. The 
result shows, overall outcome examined were not statistically significant (Carson et al., 
2012). 
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. 2.2 COMPLICATIONS OF BLOOD TRANSFUSION  
 
2.2.1 Background 
 
Blood transfusion which originate from an unrelated donor are known as allogenic red 
blood cell transfusions. It is certainly beneficial in specific situation but the used are 
accompanied by many risk and side effects. The risk of death from transfusion are very 
low and as estimated from Serious Hazard of Transfusion (SHOT) data in 2012 is 1 in 
322 580 components issued while major morbidity occur 1 in 21 413 blood components 
issued (Bolton-Maggs et al., 2013). The risk of transfusion-transmitted infection (TTI) 
by viruses like human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C 
(HCV) is much lower since modern blood banking has used highly sensitive assay for 
screening of blood donors. Nowadays, implementation of nucleotide testing for viral 
screening has further reduced the residual risk of transfusion acquired HIV, HBV and 
HCV to approximately 1 in 500,000 to 750, 000 blood exposures (Perrotta and Snyder, 
2001). 
 
In view of the incidence for TTI is low, non-infectious complication of transfusion 
therapy become relatively more important (Figure 2.3). Acute transfusion reactions and 
transfusion-associated circulatory overload carry the highest risk for morbidity and 
death(Bolton‐Maggs and Cohen, 2013). More common complication is immune-
mediated such as alloimmunization to red cells, platelet and plasma protein which can 
lead to red cells destruction, febrile non-haemolytic and allergic reaction (Taylor et al., 
2008). Based on the cumulative result from all reports in SHOT shows that, the 
commonest unpredictable transfusion reaction is an acute transfusion reaction such as 
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allergic, severe febrile or anaphylactic reaction. Ha(Bolton-Maggs et al., 2013)emolytic 
transfusion reaction (HTR) are the commonest among the potentially preventable 
complication. This type of hazard can be prevented by better pretransfusion assessment 
and monitoring. However, overall most common adverse events are caused by errors, 
resulting from the transfusion an incorrect component (Bolton-Maggs et al., 2013). 
Complications of blood transfusion were summarized in Table 2.4. 
 
 
 
Figure 2.3: Cumulative data for SHOT categories from 1996/7 to 2012 (n= 11570). Figure adapted 
from Bolton-Maggs and Cohen 2013. 
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Table 2.4: Non-infectious complication of blood transfusion 
 
Immune mediated Non-immune mediated 
 
Haemolytic transfusion reactions  
RBC Alloimmunization  
Febrile nonhemolytic transfusion 
reaction  
Allergic/Urticarial/ Anaphylactic 
reaction  
Transfusion-related acute lung injury 
(TRALI)  
Post-transfusion purpura (PTP)  
Transfusion-associated graft versus host 
disease  
Microchimerism  
 
Septic transfusion reaction  
Nonimmune haemolysis  
Miss transfusion  
Transfusion-associated circulatory 
overload  
Metabolic derangement  
Coagulation complication from massive 
transfusion 
Iron overload.  
  
 
Table adapted and modified from Hendrickson and Hillyer, 2009 
 
 
2.2.2 Red Blood Cell Alloimmunization 
 
Individuals who had exposed to RBC alloantigen through transfusion, pregnancy or 
transplantation will eventually produce antibodies against the alloantigen that expressed 
by the RBCs. The incidence of development of antibodies is still debated and ranges from 
1 to 6% in single transfusion and in certain condition can be up to 30% in multi-transfused 
patient such as in sickle cell disease, thalassemia and myelodysplastic syndrome 
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(Schonewille et al., 2006). Furthermore, about 30 to 80% of rhesus (D) negative 
individual will eventually develop anti-D upon exposure towards Rh (D) positive antigen 
(Frohn et al., 2003). The presence of RBC alloantibodies can pose serious clinical 
problems such as HTRs as well as logistic problems. It is difficult and laborious to prepare 
the compatible blood with antigen negative to that particular antibody in timely and 
properly matched for transfusion in the presence of significant antibodies. This may result 
in delay blood transfusion in emergency condition and have high risk of transfusion 
reaction. Antigenic differences, immunogenicity, dose and frequency of transfusion and 
also recipient immune status are the factors that have been suggested to influence the rates 
of alloimmunization (Zalpuri et al., 2012a). 
 
Red cell immunogenicity refers to the ability of an antigen which present on the surface 
of red blood cell to stimulate an immune response. This immune response is characterized 
by development of antibody. These RBCs antigens will elicit immune response when they 
are processed in conjunction with human leucocytes antigen (HLA) molecules on antigen 
presenting cells and are presented to the T-cell receptor on T-lymphocytes (Banchereau 
and Steinman, 1998). The derived peptide is bound to the HLA groove by a series of 
hydrogen bonds and also by protrusion of the side chains into a small cavities along the 
peptide-binding site (Chelvanayagam and Easteal, 1997). These cavities are essential for 
HLA class II binding. The recognition of RBC-derived peptide which displayed by the 
HLA class II molecule will eventually activates a specific CD4+ T cell and in turn will 
activates a specific B cells to produces a clone of antibody-producing cells (Texier et al., 
1999). This activated B cells will produce antibody towards specific antigen. 
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The immunogenicity of the antigen will depend on the polymorphism of the HLA 
proteins. The rhesus (Rh) blood group system was reported to be the most polymorphic 
of human blood groups. It consisting of at least 45 independent antigens and antibody 
towards these antigens are the most clinically significant in transfusion medicine (Avent 
and Reid, 2000). Among the rhesus group antigens, the D is known to be the most 
immunogenic whereby Kell, Kidd and Duffy antigen also implicated in alloimmunization 
with lower immunogenicity (Giblett, 1961). More than 80% of immunocompetent rhesus 
negative patients will develop anti-D once exposed to rhesus positive blood (Schonewille 
et al., 2000). The exposure can occur during pregnancy or blood transfusion. Because of 
this reason, Rh D system are included in the blood group screening and prophylactic Rh 
D negative is given to rhesus negative patients. However, this practice will not prevent 
formation of alloantibody towards other types of RBC antigen. RBC alloimmunization 
towards other group of RBC antigen can occur in up to 40% depending on the patient-
related factor and number of transfusions (Schonewille and Brand, 2005). 
 
Besides Rhesus group, the International Society of Blood Transfusion has recognized 302 
blood group antigens which belong to 1 of 29 genetically discrete blood group system. 
Antibodies to many of these antigen were potentially have clinical significant by causing 
destruction of RBC (Poole et al., 1991). Table 2.5 shows the blood group systems with 
the immunogenicity and their clinical significant. 
 
 
 
 
